Sponsors (49)
The bill channels targeted federal funding and infrastructure to accelerate brain tumor research, clinical trials, survivorship care, and equitable trial outreach — trading increased federal spending and compliance/privacy burdens (and potential diversion of research resources) for the potential of faster development and broader access to treatments for people with brain tumors.
Patients with brain tumors, researchers, and health systems will gain substantially from sustained, targeted federal investment (multi‑year appropriations and dedicated program funding) that accelerates preclinical work and early‑phase trials, increasing the likelihood of new treatments.
Patients (including rural and historically underserved communities) will have improved awareness of and access to clinical trials through outreach, broader trial eligibility, and targeted culturally competent engagement, increasing treatment options and equity in trial participation.
Researchers and clinicians will get easier, faster access to NIH-funded brain tumor biospecimens via a searchable public registry and greater transparency about specimen collections, speeding study recruitment and scientific progress.
Taxpayers face increased federal spending (multi‑million dollar annual authorizations) that could raise deficits or crowd out other federal priorities.
NIH and other research resources concentrated on brain tumor programs may divert funding away from other diseases and scientific areas, reducing support for some non‑brain‑tumor research priorities.
Public registries and new reporting requirements create administrative burdens and potential funding risks for research institutions and biobanks (staff time, compliance costs, and penalties for violations).
Based on analysis of 12 sections of legislative text.
Requires NIH reporting and public listing of NIH‑funded brain tumor biospecimens, creates funded programs for glioblastoma and cellular immunotherapies, funds outreach and survivorship pilots, and directs FDA guidance to broaden trial inclusion.
Introduced April 9, 2025 by Brian K. Fitzpatrick · Last progress April 9, 2025
Requires NIH to publicly list and disclose NIH-funded brain tumor biospecimen collections and creates new federally authorized research and outreach programs to accelerate brain tumor therapies, improve clinical-trial access, and strengthen survivorship care. Authorizes multi‑year funding for a glioblastoma therapeutics network and cellular immunotherapy team science awards, a national outreach campaign and demonstration grants, survivorship pilot grants, and directs FDA guidance to reduce routine exclusion of brain tumor patients from clinical trials.